Quantum Leap Healthcare Collaborative specializes in novel, investigator-led clinical trial designs that promote efficient use of time and resources to reach meaningful outcomes for patients.
Each QLHC-sponsored trial uses adaptive design to accelerate learning, reduce time to actionable evidence, and improve outcomes for patients.
A novel response-adaptive platform trial integrating a sequential multiple assignment randomized design that permits optimization of individual outcomes in the context of phase II drug development.
Learn more →An extension/expansion of the I-SPY COVID platform trial launched in response to the COVID pandemic, now focused on the general problem of acute respiratory distress syndrome and Acute Hypoxemic Respiratory Failure (AHRF).
Learn more →In the setting of ductal carcinoma in situ, treatment established and experimental endocrine risk-reducing medications are used in conjunction with novel imaging biomarkers to guide the use of active surveillance and develop safer more effective risk-reducing treatments.
Learn more →QLHC is transforming how research turns into care. Your support accelerates the trials, collaborations, and patient-first innovations that bring better treatments to more people, faster.
